Lexeo Therapeutics (LXEO) Competitors $8.50 +0.30 (+3.66%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$8.70 +0.20 (+2.29%) As of 05:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO vs. EVO, RCUS, STOK, LENZ, SNDX, SION, XERS, TSHA, ZYME, and NUVBShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Evotec (EVO), Arcus Biosciences (RCUS), Stoke Therapeutics (STOK), LENZ Therapeutics (LENZ), Syndax Pharmaceuticals (SNDX), Sionna Therapeutics (SION), Xeris Biopharma (XERS), Taysha Gene Therapies (TSHA), Zymeworks (ZYME), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Its Competitors Evotec Arcus Biosciences Stoke Therapeutics LENZ Therapeutics Syndax Pharmaceuticals Sionna Therapeutics Xeris Biopharma Taysha Gene Therapies Zymeworks Nuvation Bio Lexeo Therapeutics (NASDAQ:LXEO) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership. Does the media favor LXEO or EVO? In the previous week, Lexeo Therapeutics had 8 more articles in the media than Evotec. MarketBeat recorded 12 mentions for Lexeo Therapeutics and 4 mentions for Evotec. Lexeo Therapeutics' average media sentiment score of 0.72 beat Evotec's score of 0.27 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in LXEO or EVO? 60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 5.3% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is LXEO or EVO more profitable? Lexeo Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -20.14%. Evotec's return on equity of -16.94% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -94.65% -73.36% Evotec -20.14%-16.94%-8.14% Do analysts prefer LXEO or EVO? Lexeo Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 100.00%. Evotec has a consensus price target of $7.00, indicating a potential upside of 80.41%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71Evotec 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has better valuation and earnings, LXEO or EVO? Lexeo Therapeutics has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K706.15-$98.33M-$3.26-2.61Evotec$862.40M1.60-$212.18MN/AN/A Which has more risk and volatility, LXEO or EVO? Lexeo Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. SummaryLexeo Therapeutics beats Evotec on 10 of the 14 factors compared between the two stocks. Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$442.81M$2.64B$6.04B$10.51BDividend YieldN/A57.77%5.73%4.80%P/E Ratio-2.6122.5684.7027.24Price / Sales706.15536.89514.31200.41Price / CashN/A174.0137.5761.53Price / Book2.415.3612.316.74Net Income-$98.33M$33.06M$3.32B$276.59M7 Day Performance5.85%-1.31%-1.33%-0.47%1 Month Performance57.99%11.42%8.13%7.47%1 Year Performance-4.82%-1.34%73.08%34.58% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics2.7942 of 5 stars$8.50+3.7%$17.00+100.0%+6.8%$442.81M$650K-2.6158EVOEvotec2.15 of 5 stars$3.99-0.5%$7.00+75.4%+31.1%$1.42B$862.40M0.004,827Gap DownRCUSArcus Biosciences1.9901 of 5 stars$14.54+8.9%$21.14+45.4%-13.3%$1.42B$258M-4.59500Analyst ForecastHigh Trading VolumeSTOKStoke Therapeutics3.0094 of 5 stars$26.81+4.9%$25.57-4.6%+173.8%$1.40B$36.56M31.54100Analyst ForecastLENZLENZ Therapeutics1.7606 of 5 stars$46.11-5.4%$49.60+7.6%+52.2%$1.39BN/A-24.27110SNDXSyndax Pharmaceuticals3.6265 of 5 stars$16.40+5.1%$39.22+139.2%-22.8%$1.34B$23.68M-4.22110SIONSionna Therapeutics2.7188 of 5 stars$29.25-2.5%$38.00+29.9%N/A$1.32BN/A0.0035XERSXeris Biopharma2.762 of 5 stars$8.13-0.9%$7.08-12.9%+173.4%$1.32B$203.07M-38.71290TSHATaysha Gene Therapies2.3917 of 5 stars$4.42-7.1%$9.00+103.6%+159.3%$1.30B$8.33M-13.00180Gap UpZYMEZymeworks0.0676 of 5 stars$16.68-1.5%N/AN/A$1.27B$122.87M-17.20460News CoverageGap UpNUVBNuvation Bio2.8115 of 5 stars$3.77+1.6%$7.86+108.4%+54.9%$1.27B$7.87M-5.9860Analyst Forecast Related Companies and Tools Related Companies Evotec Competitors Arcus Biosciences Competitors Stoke Therapeutics Competitors LENZ Therapeutics Competitors Syndax Pharmaceuticals Competitors Sionna Therapeutics Competitors Xeris Biopharma Competitors Taysha Gene Therapies Competitors Zymeworks Competitors Nuvation Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXEO) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
